SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Pharmos(PARS)
PARS 2.700+13.6%Jan 21 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Omer Shvili who wrote (1197)8/30/1998 9:35:00 PM
From: arnie h  Read Replies (2) of 1491
 
Omer: Thanks for a great summary and before I take issue with one point, let me note I just got 5 copies of the annual report because I hold PARS in 5 separate accounts.

The area of my concern is with your point that nobody knows the results of HU211. You then proceed to make a case for the company knowing that the results are positive. I have to say it makes me nervous when there is a hint that people know the results of double blind studies before they are unblinded. It turns out the FDA in this country tends to penalize firms who do this. As a long term investor myself, I tend to want to avoid any unneccessary delays that might result from such an event. Hopefully, the company is acting in a fashion that involves contingency planning rather than active knowledge.

Regardless, PARS should be a minimum of $6 or so by the next millenium which as you pointed out ain't too bad.

Regards,
Arnie
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News